Campylobacter infection in adult patients with primary antibody deficiency

Jérémie Dion, Marion Malphettes, Lucie Benejat, Francis Megraud, Alain Wagnier, David Boutboul, Lionel Galicier, Vincent Le Moing, Patrick Giraud, Arnaud Jaccard, et al.

► To cite this version:

Jérémie Dion, Marion Malphettes, Lucie Benejat, Francis Megraud, Alain Wagnier, et al.. Campylobacter infection in adult patients with primary antibody deficiency. Journal of Allergy and Clinical Immunology: In Practice, 2019, 7 (3), pp.1038-1041.e4. 10.1016/j.jaip.2018.06.014 . hal-02509193

HAL Id: hal-02509193

<https://hal.science/hal-02509193>

Submitted on 22 Oct 2021

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Distributed under a Creative Commons Attribution - NonCommercial| 4.0 International License

Campylobacter infection in adult patients with primary antibody deficiency

Jérémy Dion¹, MD, Marion Malphettes^{1,2}, MD, Lucie Bénéjat³, MS, Francis Megraud³, MD, Alain Wagnier⁴, MD, PhD, David Boutboul¹, MD, PhD, Lionel Galicier^{1,5}, MD, Vincent Le Moing⁶, MD, PhD, Patrick Giraud⁷, MD, Arnaud Jaccard⁸, MD, PhD, Raphaële Nove-Josserand⁹, MD, Claire Fieschi^{1,2}, MD, PhD, Eric Oksenhendler^{1,5}, MD, PhD, and Laurence Gérard^{1,5}, MD for the DEFI study group.

¹ Département d'Immunologie Clinique, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, France.

² INSERM U1126, Centre Hayem, Hôpital Saint-Louis, Paris, France

³ Centre National de Référence des Campylobacters et Hélicobacters, Laboratoire de Bactériologie, Université de Bordeaux, Bordeaux, France.

⁴ Département de Microbiologie, Hôpital Saint-Louis, Assistance publique-Hôpitaux de Paris, France.

⁵ EA3518, Université Paris VII Denis Diderot, Paris, France

⁶ Département des Maladies Infectieuses et Tropicales, Centre Hospitalier Régional de Montpellier, France.

⁷ Département de Néphrologie et Médecine Interne, Clinique du Pont de Chaume, Montauban, France.

⁸ Département d'Hématologie Clinique, CHU de Limoges, France

⁹ Département de Médecine Interne, Centre Hospitalier Lyon-Sud, Lyon, France

Corresponding author: Dr Laurence Gérard. Département d'Immunologie Clinique. Hôpital Saint-Louis. 1, avenue Claude Vellefaux. 75010 Paris. France.

Tel: 33(1) 42 49 91 77

Fax: 33(1) 42 49 94 72

Mail: laurence.gerard@aphp.fr

Funding. DEFI study was initially supported by public national program for clinical research (PHRC, INSERM RBM0333). The funding source had no role in the present ancillary study.

35

36 **Potential conflicts of interest.** L.B. has received grants for her institution from Allergan, and

37 support for travel/accomodations/meeting expenses from R-Biopharm and Mobidiag. F.M.

38 has received grants from Allergan, and payment for lectures including service on speakers

39 bureaus from Allergan and Takeda. L.Ga. has been consultant for Baxalta, has received

40 payment for development of educational presentations from Amgen, Roche, Janssen

41 Pharmaceuticals, GlaxoSmithKline, Pfizer, Raison et Santé, Baxalta, and support for

42 travel/accomodations/meeting expenses from Janssen Pharmaceuticals, GlaxoSmithKline, and

43 Shire. A.J. has received payment for lectures from Janssen Pharmaceuticals and Abbvie,

44 travel/accomodations/meeting expenses from Janssen Pharmaceuticals, Celgen, Takeda, and

45 Gilead Sciences. E.O. has received personal fees from CSL Behring, Shire, non financial

46 support from Janssen Pharmaceuticals, has served on advisory boards for CSL Behring and

47 Shire. L.Gé. has received support for travel/accomodations/meeting expenses from Janssen

48 Pharmaceuticals and Gilead Sciences.

49 J.D., M.M., A.W., D.B., V.L.M., P.G., R.N.J.: no conflict

50

51 **Word count:** 987

52

53 **Clinical implication Box**

54 In patients with severe primary antibody deficiency, Campylobacter infection is a major cause of
55 chronic or recurrent diarrhea. The frequent recurrence with different strains and the high frequency
56 of bacteremia suggest an increased susceptibility to this pathogen in this population.

57

58 **To the editor:**

59 Primary antibody deficiency (PAD) is characterized by a defective immunoglobulin
60 production and recurrent infections, mostly involving respiratory and gastrointestinal tracts.

61 Chronic or recurrent diarrhea is reported in up to 23% (1). Campylobacter infection is a
62 common cause of infectious diarrhea, reported in 1.2 to 7.5% of patients with common
63 variable immunodeficiency (CVID), the most frequent PAD (1-3). The aim of this study was
64 to describe Campylobacter infection in patients with PAD included in a large nationwide
65 study and analyze factors associated with susceptibility to this pathogen.

66 The DEFI (DEFicit Immunitaire) study is an ongoing large cross-sectional French
67 multicentric study of adults with PAD, with retrospective collection of clinical data (2). All
68 patients with a history of bacteriologically documented Campylobacter infection were
69 identified, and clinical data were collected for each episode. Factors associated with recurrent
70 infection were assessed as odds ratio (OR) and 95% confidence interval (CI), calculated by
71 means of simple regression analysis. In patients with available material, strains of each
72 episode were characterized using molecular analysis and compared (Table E1A in the Online
73 Repository). A comparison of immunodeficiency-related characteristics of patients with and
74 without Campylobacter infection was performed in the homogenous group of CVID patients.
75 The control group included CVID patients from DEFI centers who confirmed that patients did
76 not develop Campylobacter infection after enrollment (Figure E1 in the Online Repository).
77 After correction for multiple comparisons, a $P < 0.016$ was considered significant.

78 Since 2004, 790 patients with PAD were included in the DEFI study, and 51 presented with
79 Campylobacter infection (6.5%). Medical chart was available for review in 45 patients.

80 Characteristics of these patients at the time of enrollment in DEFI are detailed in Table E2 in
81 the Online Repository. A total of 97 episodes were recorded (Table 1). The overall

82 distribution of *Campylobacter* species was unremarkable. Antimicrobial susceptibility testing
83 revealed a higher resistance rate than in the general population for each antibiotic tested (See
84 Figure E2 in the Online Repository). A comorbidity was present in 55% of *Campylobacter*
85 episodes, and a coinfection by other enteropathogens in 10%. Most patients were receiving
86 concomitant therapy at the time of episode. One patient with end-stage cirrhosis died with
87 *Campylobacter* bacteremia. Overall, bacteremia was observed in 24 episodes (13 patients),
88 and was associated with extra-intestinal complication in 10 episodes.

89 Nineteen patients (42%) presented with recurrent (2 to 11) episodes. Factors associated with
90 recurrent episodes were the presence of comorbidity (OR, 3.7 [95%CI, 1.1-13.1]), and
91 undetectable serum IgA (OR, 8.6 [95%CI, 1.1-21.2]). None of these factors remain significant
92 in multivariate analysis. Molecular study of a subset of 18 strains from five patients with
93 recurrent infections demonstrated that all strains were different, even when the antimicrobial
94 susceptibility testing was similar and when the episodes occurred closely over time (Table
95 E1B in the Online Repository). Compared to 288 CVID patients without *Campylobacter*
96 infection, CVID patients with *Campylobacter* infection presented a higher prevalence of
97 consanguinity and a more severe CVID phenotype, with more frequent disease-related
98 complications, lower serum immunoglobulin levels, lower B and NK cells, and a trend for
99 lower naive CD4+T cell at the time of enrollment in the DEFI study (Table 2).

100 This study is the first description of a large series of patients with PAD and *Campylobacter*
101 infection. The 6.5% prevalence was probably underestimated due to the retrospective nature
102 of the clinical data collection. In this population symptoms were mostly restricted to an
103 isolated, frequently severe, chronic watery diarrhea, with associated malnutrition, leading to
104 repeated hospitalizations and impaired quality of life. Other digestive symptoms and fever
105 were less frequent than those observed in the general population (4). In contrast, bacteremia
106 as well as extra-digestive localizations were more frequent (25% versus 0.15-2%, and 22%

versus 7%, respectively) (5). Despite frequent hospitalizations, the overall prognosis was good. Recurrence rate was high (42%) compared to 1.2% in the general population (6), and was associated with extra-intestinal comorbidity and undetectable IgA level in univariate analysis. Although limited by the number of available strains, molecular profile of strains from patients with recurrent infections were all different. Thus, we could hypothesize that reinfection is more likely than persistent colonization, although colonization with multiple strains cannot be excluded.

Conditions associated with the occurrence of *Campylobacter* infection were described in an analysis restricted to a large homogenous group of 325 CVID patients. The present data suggest that hypochlorhydria, either PPI-induced or associated with autoimmune gastritis, might play an important role in the pathogenesis of this infection. Almost all CVID-associated complications, particularly liver and gastrointestinal disease, were more frequent in patients with *Campylobacter* infection. A more severe immune deficiency at CVID diagnosis, with lower serum immunoglobulin level was also observed. Even in patients with immunoglobulin replacement therapy, IgM and IgA levels remain very low. IgA and IgM, almost absent in immunoglobulin batches, are more important than IgG in *Campylobacter* immunity (7). B-cell and specifically switch memory B cell deficiency was also more severe in CVID patients with *Campylobacter* infection than in patients without. This is in line with the high prevalence of *Campylobacter* infection observed in Good syndrome and XLA, two conditions associated with no circulating B cells (Figure E1 in the Online Repository). B-cells are also known to be important for the dialogue between immune system and gut microbiota, whose composition is important for *Campylobacter* immunity (8). T-cells may also play an important role, with a trend for decreased naive T-cells. Indeed, fifteen patients (40%) presented with a severe associated T-cell defect and could be considered as Late Onset Combined Immunodeficiency (data not shown) (9).

132 In patients with PAD, Campylobacter infection is quite frequent and seems to be related to
133 various factors adding up together: severity of the immune deficiency, PAD complication, and
134 associated antibiotics, immunosuppressive therapies and PPI. It is characterized by a high
135 frequency of recurrence and bacteremia. Recurrence is associated with the presence of
136 comorbidity and IgA defect, and turned out to be due to reinfection more than to persistent
137 colonization, suggesting a specific susceptibility despite immunoglobulin substitution.

138

References

1. Cunningham-Rundles C, Bodian C. Common Variable Immunodeficiency: Clinical and Immunological Features of 248 Patients. *Clin Immunol* 1999;92:34–48.
2. Oksenhendler E, Gérard L, Fieschi C, Malphettes M, Mouillot G, Jaussaud R, et al. Infections in 252 patients with common variable immunodeficiency. *Clin Infect Dis* 2008;46:1547–54.
3. Chapel H, Lucas M, Patel S, Lee M, Cunningham-Rundles C, Resnick E, et al. Confirmation and improvement of criteria for clinical phenotyping in common variable immunodeficiency disorders in replicate cohorts. *J Allergy Clin Immunol*. 2012 Nov;130(5):1197–1198.e9.
4. Peterson MC. Clinical aspects of *Campylobacter jejuni* infections in adults. *West J Med*. 1994 Aug;161(2):148–52.
5. Nielsen H, Hansen KK, Gradel KO, Kristensen B, Ejlersen T, Østergaard C, et al. Bacteraemia as a result of *Campylobacter* species: a population-based study of epidemiology and clinical risk factors. *Clin Microbiol Infect* 2010 Jan;16(1):57–61.
6. Arsenault J, Ravel A, Michel P, Berke O, Gosselin P. Do patients with recurrent episodes of campylobacteriosis differ from those with a single disease event? *BMC Public Health* 2011;11:32.
7. Janssen R, Krogfelt KA, Cawthraw SA, van Pelt W, Wagenaar JA, Owen RJ. Host-Pathogen Interactions in *Campylobacter* Infections: the Host Perspective. *Clin Microbiol Rev* 2008;21:505–18.
8. Dicksved J, Ellström P, Engstrand L, Rautelin H. Susceptibility to *Campylobacter* infection is associated with the species composition of the human fecal microbiota. *mBio* 2014;5:e01212-4.
9. Bertinchamp R, Gérard L, Boutboul D, Malphettes M, Fieschi C, Oksenhendler E, et al. Exclusion of Patients with a Severe T-Cell Defect Improves the Definition of Common Variable Immunodeficiency. *J Allergy Clin Immunol Pract* 2016;4:1147–57.

Table 1. Description of 97 *Campylobacter* episodes in 45 patients included in the DEFI study. Results are expressed as median (IQR), or number/number of episode with available data (%).

Characteristics	No. or median	% or IQR
Clinical features		
Digestive symptoms	81/87	93
Diarrhea	79	91
Chronic diarrhea	39	45
Abdominal pain	15	17
Vomiting	3	3
Fever	21/84	25
Bacteremia	24/97	25
Extra-intestinal symptoms	18/83	22
Respiratory	7	8
Osteo-articular	5	6
Urinary	2	2
Cutaneous	5	6
Concomitant infection ^a	17/84	20
Comorbidity ^b	53	55
Complications		
Hospitalisation	33/85	39
Duration, days	7	3-14
Late complications ^c	9/97	9
Current therapy at <i>Campylobacter</i> diagnosis		
Immunosuppressive drugs ^d	35/88	40
Proton pump inhibitors	41/81	51
Ig replacement therapy	79/90	87
Antibiotic prophylaxis	30/84	35
Serum Ig levels, g/L		
	n=37	
IgG	6.5	03-09
IgA	0.05	0-0.3
Undetectable IgA level	31	83
IgM	0.12	0.05-0.6
Undetectable IgM level	20	57
<i>Campylobacter</i> species		
	n=97	
<i>Campylobacter jejuni</i>	55	56
<i>Campylobacter coli</i>	19	20
Other <i>Campylobacter</i> species	4	4
Unspecified	19	20

Abbreviations: Ig, immunoglobulin; IQR, interquartile range.

^a Digestive infection in 10 cases: *Helicobacter pylori* gastritis (n=4), lamblasis (n=2), *Clostridium difficile* colitis (n=3), cytomegalovirus colitis (n=2); urinary infection in 4 cases; respiratory infection in 3 cases.

173 ^b Diabetes (n=2 patients), chronic liver disease (n=13 patients), blood neoplasia (n=3
174 patients), or transplantation (n=1 patient).
175 ^c Reactive arthritis (n=8), relapsing erythema nodosum (n=1).
176 ^d Prednisone(n=9), budesonide (n=18), TNF α (tumor necrosis factor alpha)-blocker (n=2),
177 methotrexate (n=7), mycophenolate (n=2).
178

Table 2. Comparison between common variable immunodeficiency (CVID) patients with Campylobacter infection (Campylo pos) and without Campylobacter infection (Campylo neg) at enrollment in the DEFI study. Results are expressed as median (IQR) or number (%).

Characteristics	Campylo pos (n=37)	Campylo neg (n=288)	P
Population			
Female	22 (59)	172 (58)	0.98
Consanguinity	10 (27)	27 (10)	0.002*
Age at CVID diagnosis	32 (25-44)	37 (26-50)	0.17
Clinical complications			
Infection only	10 (27)	167 (58)	<10 ⁻³ *
Disease-Related Complication ^a	27 (73)	104 (36)	<10 ⁻³ *
Lymphoid proliferation	20 (54)	75 (26)	<10 ⁻³ *
Granulomatosis	11 (30)	39 (13)	0.01*
Autoimmune cytopenia	8 (22)	48 (17)	0.45
Opportunistic infection	10 (27)	22 (8)	0.001*
Chronic liver disease ^b	15 (40)	42 (15)	<10 ⁻³ *
Gastrointestinal complication	31 (84)	117 (41)	<10 ⁻³ *
Pernicious anemia	5 (13)	4 (1)	0.001*
Villous atrophy	8 (22)	15 (5)	0.002*
IBD	4 (11)	11 (4)	0.07
Digestive granuloma	3 (8)	6 (2)	0.07
Other GI tract infection ^c	16 (43)	43 (15)	<10 ⁻³ *
Acute recurrent diarrhea	12 (32)	27 (9)	0.01*
Chronic diarrhea	23 (62)	56 (19)	<10 ⁻³ *
Biology at CVID diagnosis			
Serum Ig level, g/L			
IgG	1.7 (0.84-2.8)	3.0 (1.3-4.3)	0.005*
IgA	0.07 (0.06-0.32)	0.25 (0.07-0.46)	0.008*
IgM	0.19 (0.06-0.42)	0.22 (0.11-0.50)	0.05
Blood cell count			
Hemoglobin level, g/dL	13 (11-14)	14 (13-15)	0.44
Platelet count, x10 ⁹ /L	202 (109-274)	209 (167-260)	0.16
Neutrophil count, x10 ⁶ /L	4000 (2850-5760)	3700 (2850-5470)	0.60
Lymphocyte count, x10 ⁶ /L	1406 (662-1918)	1371 (1025-1866)	0.44
CD3+ T cells	1107 (563-1658)	1063 (789-1426)	0.95
CD4+	555 (305-743)	561 (398-833)	0.35
Naive CD4+ ^d	63 (16-213)	125 (48-271)	0.02
CD19+ B cells	51 (13-149)	101 (49-173)	0.03
<1%	9 (25)	26 (9)	0.008*
SMB cells ^e	0.3 (0.1-2.5)	2.7 (0.8-7.5)	<10 ⁻³ *
NK cells	71 (37-122)	106 (62-195)	0.008*

184 Abbreviations: CVID, common variable immunodeficiency; IBD, inflammatory bowel
185 disease; GI, gastrointestinal; Ig, immunoglobulin; SMB, switch memory B cells
186 * Significant P value (<0.016), after correction for multiple comparisons
187 ^a Disease-Related Complication: lymphoid proliferation including granuloma, autoimmune
188 cytopenia or enteropathy with villous atrophy (3)
189 ^b Chronic liver disease in patients with CVID and Campylobacter infections was portal
190 hypertension (n=4), nodular regenerative hyperplasia (n=3), granulomatosis (n=6), lymphoid
191 hyperplasia (n=5), cholangitis (n=1) and other (n=8)
192 ^c Excluding Campylobacter
193 ^d Naive CD4⁺ T cells CD4⁺CD45RA⁺CCR7⁺
194 ^e Switch memory B cells CD19⁺IgD⁻CD27⁺

Figure E1.

Abbreviations: PAD, primary antibody deficiency; CVID, common variable immunodeficiency; XLA, X-linked agammaglobulinemia, D, deficiency.

^a Patient with CD40 ligand deficiency

Figure E2.

Abbreviation: AMC : Amoxicillin-Clavulanate; TMP-SMX, trimetoprim-sulfamethoxazole;
NA, not available.